Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SenL_19 CAR T Cells for Refractory B Cell Malignancy
NCT02963038Phase 2
Key facts
- Status
- Unknown
- Start
- Jun 2016
- Primary completion
- Jun 2017
- Countries
- 1
- Sponsor
- Senlang Bio
- Modality
- CAR-T Cells
- Drugs
- SenL_19
- Conditions
- B-cell leukemia (BCL)B cell lymphoma
01
Overview
Phase 2, open-label, single-arm trial of SenL_19 in B-cell leukemia (BCL) and B cell lymphoma, sponsored by Senlang Bio. Primary endpoint: Tumor load at 24 months. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
CD19 CAR T cells
Autologous CD19-targeting CAR T cells
03
Who it enrols
Patients with relapsed/refractory B-cell lymphoma or leukemia who have failed chemotherapy or stem cell transplantation, aged 1-70 years, with measurable lesions and adequate organ function.
04
Endpoints
Primary
Tumor load
Secondary
CAR T cell persistence
Beyond the preview
Go deeper on NCT02963038.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963038.